C-Fos Expression is a Molecular Predictor of Progression and Survival in Epithelial Ovarian Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2008 Oct 16

PMID 18854825

Citations 67

Authors

S Mahner

C Baasch

J Schwarz

S Hein

L Wolber

F Janicke

K Milde-Langosch

Affiliations

Soon will be listed here.

Abstract

Members of the Fos protein family dimerise with Jun proteins to form the AP-1 transcription factor complex. They have a central function in proliferation and differentiation of normal tissue as well as in oncogenic transformation and tumour progression. We analysed the expression of c-Fos, FosB, Fra-1 and Fra-2 to investigate the function of Fos transcription factors in ovarian cancer. A total of 101 patients were included in the study. Expression of Fos proteins was determined by western blot analysis, quantified by densitometry and verified by immunohistochemistry. Reduced c-Fos expression was independently associated with unfavourable progression-free survival (20.6, 31.6 and 51.2 months for patients with low, moderate and high c-Fos expression; P=0.003) as well as overall survival (23.8, 46.0 and 55.5 months for low, moderate and high c-Fos levels; P=0.003). No correlations were observed for FosB, Fra-1 and Fra-2. We conclude that loss of c-Fos expression is associated with tumour progression in ovarian carcinoma and that c-Fos may be a prognostic factor. These results are in contrast to the classic concept of c-Fos as an oncogene, but are supported by the recently discovered tumour-suppressing and proapoptotic function of c-Fos in various cancer types.

Citing Articles

Drug-resilient Cancer Cell Phenotype Is Acquired via Polyploidization Associated with Early Stress Response Coupled to HIF2α Transcriptional Regulation.

Carroll C, Manaprasertsak A, Boffelli Castro A, van den Bos H, Spierings D, Wardenaar R Cancer Res Commun. 2024; 4(3):691-705.

PMID: 38385626 PMC: 10919208. DOI: 10.1158/2767-9764.CRC-23-0396.

Role of Fra-2 in cancer.

Rampioni Vinciguerra G, Capece M, Scafetta G, Rentsch S, Vecchione A, Lovat F Cell Death Differ. 2023; 31(2):136-149.

PMID: 38104183 PMC: 10850073. DOI: 10.1038/s41418-023-01248-4.

Protection of c-Fos from autophagic degradation by PRMT1-mediated methylation fosters gastric tumorigenesis.

Kim E, Rahmawati L, Aziz N, Kim H, Kim J, Kim K Int J Biol Sci. 2023; 19(12):3640-3660.

PMID: 37564212 PMC: 10411464. DOI: 10.7150/ijbs.85126.

Spatial resolution of cellular senescence dynamics in human colorectal liver metastasis.

Garbarino O, Lambroia L, Basso G, Marrella V, Franceschini B, Soldani C Aging Cell. 2023; 22(7):e13853.

PMID: 37157887 PMC: 10352575. DOI: 10.1111/acel.13853.

Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo.

Genduso S, Freytag V, Schetler D, Kirchner L, Schiecke A, Maar H J Hematol Oncol. 2023; 16(1):23.

PMID: 36932441 PMC: 10022201. DOI: 10.1186/s13045-023-01413-9.

References

Spentzos D, Levine D, Ramoni M, Joseph M, Gu X, Boyd J . Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004; 22(23):4700-10. DOI: 10.1200/JCO.2004.04.070. View

Bamberger A, Methner C, Lisboa B, Stadtler C, Schulte H, Loning T . Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer. 1999; 84(5):533-8. DOI: 10.1002/(sici)1097-0215(19991022)84:5<533::aid-ijc16>3.0.co;2-j. View

Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso L, Orlowska-Volk M . Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2004; 24(6):1053-65. DOI: 10.1038/sj.onc.1208298. View

Hartmann L, Lu K, Linette G, Cliby W, Kalli K, Gershenson D . Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005; 11(6):2149-55. DOI: 10.1158/1078-0432.CCR-04-1673. View

Milde-Langosch K, Bamberger A, Rieck G, Grund D, Hemminger G, Muller V . Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer. 2005; 92(12):2206-15. PMC: 2361826. DOI: 10.1038/sj.bjc.6602655. View

Milde-Langosch K . The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005; 41(16):2449-61. DOI: 10.1016/j.ejca.2005.08.008. View

Graves M, Zhou L, MacDonald G, Mueller C, Roskelley C . Regulation of the BRCA1 promoter in ovarian surface epithelial cells and ovarian carcinoma cells. FEBS Lett. 2007; 581(9):1825-33. DOI: 10.1016/j.febslet.2007.03.072. View

Winter 3rd W, Maxwell G, Tian C, Carlson J, Ozols R, Rose P . Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25(24):3621-7. DOI: 10.1200/JCO.2006.10.2517. View

Jin S, Kim J, Kim M, Yang H, Lee H, Lee H . Prognostic significance of loss of c-fos protein in gastric carcinoma. Pathol Oncol Res. 2007; 13(4):284-9. DOI: 10.1007/BF02940306. View

10.

Teng C . Protooncogenes as mediators of apoptosis. Int Rev Cytol. 2000; 197:137-202. DOI: 10.1016/s0074-7696(00)97004-9. View

11.

Pegram M, Konecny G, Slamon D . The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res. 2000; 103:57-75. DOI: 10.1007/978-1-4757-3147-7_4. View

12.

Welsh J, Zarrinkar P, Sapinoso L, Kern S, Behling C, Monk B . Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2001; 98(3):1176-81. PMC: 14728. DOI: 10.1073/pnas.98.3.1176. View

13.

Shaulian E, Karin M . AP-1 in cell proliferation and survival. Oncogene. 2001; 20(19):2390-400. DOI: 10.1038/sj.onc.1204383. View

14.

Jochum W, Passegue E, Wagner E . AP-1 in mouse development and tumorigenesis. Oncogene. 2001; 20(19):2401-12. DOI: 10.1038/sj.onc.1204389. View

15.

Siegmund D, Mauri D, Peters N, Juo P, Thome M, Reichwein M . Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway. J Biol Chem. 2001; 276(35):32585-90. DOI: 10.1074/jbc.M100444200. View

16.

Bamberger A, Milde-Langosch K, Rossing E, Goemann C, Loning T . Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J Cancer Res Clin Oncol. 2001; 127(9):545-50. DOI: 10.1007/s004320100255. View

17.

Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. DOI: 10.1200/JCO.2002.20.5.1248. View

18.

Huang Y, Boskovic G, Niles R . Retinoic acid-induced AP-1 transcriptional activity regulates B16 mouse melanoma growth inhibition and differentiation. J Cell Physiol. 2002; 194(2):162-70. DOI: 10.1002/jcp.10199. View

19.

Tingulstad S, Skjeldestad F, Halvorsen T, Hagen B . Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol. 2003; 101(5 Pt 1):885-91. DOI: 10.1016/s0029-7844(03)00123-6. View

20.

du Bois A, Luck H, Meier W, Adams H, Mobus V, Costa S . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-9. DOI: 10.1093/jnci/djg036. View